

1 **Longitudinal proteomic investigation of COVID-19 vaccination**

2

3 **Yingrui Wang^{1,2,3,4,#}, Qianru Zhu^{6,7,#}, Rui Sun^{1,2,3,4,#}, Xiao Yi^{1,2,3,5,#}, Lingling**
4 **Huang⁵, Yifan Hu⁵, Weigang Ge⁵, Huanhuan Gao^{1,2,3,4}, Xinfu Ye⁵, Yu Song⁸, Li**
5 **Shao^{6,9}, Yantao Li⁵, Jie Li^{10,11,*}, Tiannan Guo^{1,2,3,4,*}, Junping Shi^{6,12,*}**

6

7 ¹Westlake Intelligent Biomarker Discovery Lab, Westlake Laboratory of Life Sciences
8 and Biomedicine, Hangzhou 310024, Zhejiang, China;

9 ²Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural
10 Biology of Zhejiang Province, School of Life Sciences, Westlake University,
11 Hangzhou 310024, Zhejiang Province, China;

12 ³Institute of Basic Medical Sciences, Westlake Institute for Advanced Study,
13 Hangzhou 310024, Zhejiang Province, China;

14 ⁴Center for Infectious Disease Research, Westlake University, 18 Shilongshan Road,
15 Hangzhou 310024, Zhejiang, China;

16 ⁵Westlake Omics (Hangzhou) Biotechnology Co., Ltd., Hangzhou 310024, China;

17 ⁶Department of Translational Medicine Platform, The Affiliated Hospital of Hangzhou
18 Normal University, Hangzhou, Zhejiang, China;

19 ⁷State Key Laboratory of Quality Research in Chinese Medicines, Faculty of Chinese
20 Medicine, Macau University of Science and Technology, Macau, P.R. China;

21 ⁸The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University,
22 Hangzhou, Zhejiang, China;

23 ⁹Medical college of Hangzhou Normal University, Hangzhou, Zhejiang, China;

24 ¹⁰Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated
25 Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China;

26 ¹¹Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, Jiangsu,
27 China;

28 ¹²Department of Infectious & Hepatology Diseases, The Affiliated Hospital of
29 Hangzhou Normal University, Hangzhou, Zhejiang, China.

30 #These authors contributed equally.

31 *Correspondence: ljjier@sina.com ; quotiannan@westlake.edu.cn ;
32 20131004@hznu.edu.cn

33

34

35

36 **Abstract**

37 Although the development of COVID-19 vaccines has been a remarkable success,
38 the heterogeneous individual antibody generation and decline over time are unknown
39 and still hard to predict. In this study, blood samples were collected from 163
40 participants who next received two doses of an inactivated COVID-19 vaccine
41 (CoronaVac®) at a 28-day interval. Using TMT-based proteomics, we identified 1715
42 serum and 7342 peripheral blood mononuclear cells (PBMCs) proteins. We proposed
43 two sets of potential biomarkers (seven from serum, five from PBMCs) using
44 machine learning, and predicted the individual seropositivity 57 days after vaccination
45 (AUC = 0.87). Based on the four PBMC's potential biomarkers, we predicted the
46 antibody persistence until 180 days after vaccination (AUC = 0.79). Our data
47 highlighted characteristic hematological host responses, including altered lymphocyte
48 migration regulation, neutrophil degranulation, and humoral immune response. This
49 study proposed potential blood-derived protein biomarkers for predicting
50 heterogeneous antibody generation and decline after COVID-19 vaccination,
51 shedding light on immunization mechanisms and individual booster shot planning.

52 **Running head:** Longitudinal proteomic profiling of COVID-19 vaccination

53 **Keywords**

54 COVID-19, vaccination, proteomics, neutralizing antibodies (NAbs), machine learning

55 **Abbreviations**

56 AGC (automatic gain control), AUC (area under curve), B-H (Benjamini-Hochberg),
57 COVID-19 (coronavirus disease 2019), CV (coefficients of variance), DEPs
58 (differentially expressed), ECM (extracellular matrix), FDR (false discovery rate),
59 GMT (Geometric Mean Titers), GSVA (gene-set variation analysis), IFN (interferon),
60 MALFD (metabolic associated fatty liver disease), PBMCs (peripheral blood
61 mononuclear cells), SARS-Cov-2 (severe acute respiratory syndrome coronavirus 2),
62 SHAP (SHapley Additive exPlanations), T2DM (Type 2 diabetes mellitus)

63 **Highlights**

- 64 1. Longitudinal proteomics of PBMC and serum from individuals vaccinated with
65 CoronaVac®.
- 66 2. Machine learning models predict neutralizing antibody generation and decline
67 after COVID-19 vaccination.
- 68 3. The adaptive and the innate immune responses are stronger in the seropositive
69 groups (especially in the early seropositive group).
- 70 4. Vaccine-induced immunity involves in lymphocyte migration regulation,
71 neutrophil degranulation, and humoral immune response.

72 Introduction

73 The global public health crisis and the social disruption caused by the coronavirus
74 disease 2019 (COVID-19) pandemic have prompted the emergency use of speedily
75 developed vaccines. As of October 2022, over 12 billion doses had been
76 administered globally (WHO, 2022-10-25), although the vaccination distribution is
77 significantly unbalanced (van der Graaf et al., 2022). Previous studies have reported
78 that NAb responses elicited by an inactivated vaccine (CoronaVac[®]) and an mRNA
79 vaccine (BNT162b2) persisted for 6-8 months after full-schedule vaccination and
80 declined to varying degrees (Falsey et al., 2021; Zeng et al., 2021). Therefore,
81 multiple vaccine boosters and prolonged intervals between vaccine doses are
82 needed to maintain the immunity against SARS-CoV-2 (Zhao et al., 2022), and could
83 induce a robust humoral immune response (Ai et al., 2022). Several studies reported
84 the dynamics of NAb generation and the molecules dysregulation occurring after
85 vaccinations (Liu et al., 2021; Wang et al., 2022). In a BMJ meta-analysis has shown
86 that seroconversion rates and antibody titers after COVID-19 vaccines are
87 significantly lower in immunocompromised patients than immunocompetent
88 individuals (Lee et al., 2022), including immune-mediated inflammatory disorders,
89 solid cancers, organ transplant recipients and hematological cancers. While to the
90 best of our knowledge based on literature search, no study has systematically
91 reported heterogeneous hematological host responses to vaccination in both PBMCs
92 and serum. There is currently no known biomarker for predicting the effectiveness of
93 vaccines.

94 In this study, we investigated the host response to Sinovac-CoronaVac[®]. Specifically,
95 we analyzed the proteome of the peripheral blood mononuclear cells (PBMCs) and
96 the sera of a vaccination recipients at different time points. We developed a method
97 to predict the host responses to vaccination. Specifically, we predicted who cannot
98 generate antibodies and whose NAb tend to disappear earlier than six months after
99 the vaccination. This information would help plan targeted boosters and decide the
100 types and intervals of the vaccinations.

101

102 Results

103 *Clinical and proteomics profiling before inactivated SARS-CoV-2 vaccination*

104 Between January and February 2021, a total of 163 vaccination recipients were
105 recruited in the discovery (N = 137) and the test (N = 26) cohorts (Figures 1A and
106 1B). The average age was 39.8 years in the discovery cohort and 41.6 years in the
107 test cohort. Besides, most indexes of biochemical and hematology were not
108 significantly different between the two cohorts. More details are shown in Tables 1-2,
109 Table S1, and Figure S1. All the participants received the first dose of CoronaVac[®] at
110 day 0 (D0) and the second after 28 days (D28). The qualitative detection of SARS-
111 CoV-2 NAb and spike-specific IgG was done at D0, D28, day 57 (D57), and day 180
112 (D180). By D28, 19.6% of all participants (N = 32) were NAb seropositive (Group 2,
113 the early seropositive group). By D57, the percentage of seropositive participants

114 reached 88.3% (N = 144; Group 1+2, which included Group 1, the late seropositive
115 group). The remaining 11.7% (N = 19) still had seronegative results (Group 0, the
116 seronegative group). Within Group 1+2, 33.1% (N = 42) were still positive at D180
117 (Group 4, the persistently seropositive group), while the remaining ones became
118 seronegative (Group 3) (Figure 1A). Besides, 10% of participants in Group 0 were
119 IgG seropositive on day 28, which rising to 100% by day 57 and decreasing to 83%
120 by day 180. However, 30% of participants in Group 1+2 were IgG seropositive on day
121 28, which rising to 100% by day 57 and decreasing to 88% by day 180 (Figure 1C).
122 According to multivariable logistic regression analysis, we found that NAb titers at
123 D28 were positively associated with seropositivity of neutralizing antibodies at D57
124 after adjusting age, sex, BMI and diastolic blood pressure. Then, we also identified
125 that NAb titers at D28 and D57 could as independent predictors for seropositive of
126 D180 after adjusting covariates (Figure S1). Blood samples were collected from all
127 participants before their first vaccine dose, then at D28 and D57. Serum and PBMCs
128 were extracted from all blood samples for proteomic profiling.
129 TMT-based analysis involved 528 samples, including pooled controls for aligning
130 data from different batches to evaluate quantitative accuracy, and technical replicates
131 for evaluating the reproducibility of the assay or technique. These samples were
132 distributed into 33 batches from three time points: D0, D28, and D57. We quantified
133 7342 PBMC proteins and 1715 serum proteins (Table S2; Figures 1A and S2A). The
134 median coefficients of variance (CV) for the pooled samples were 15.35% and
135 19.32% for the PBMC and the serum data, respectively (Figure S2B). The Pearson
136 correlation coefficients of the technical replicates were 98.09% and 96.82% for
137 PBMC and serum, respectively (Figure S2C). These results showed the robustness
138 of our data and its relatively high consistency and reproducibility.

139 ***Machine learning model for predicting the antibody generation***

140 We next developed a set of models for predicting the seropositivity of individuals 57
141 days after their first vaccination dose and 28 days after their second one (at D57)
142 based on the proteomics and clinical indicators collected prior to both doses (at D0).
143 Machine learning models were developed using XGBoost (Chen and Guestrin,
144 2016)(Figure 2A). Proteins or clinical indicators with a significant difference (p-value
145 < 0.05) between the two classes and with $|\log_2(\text{fold change})| > 0.25$ in the discovery
146 dataset were included in our final feature set. Then, some sparse proteins (NA rate >
147 50%) were also removed. We optimized the models' parameters in the discovery
148 dataset (Cohort 1), and generated a model based on the five PBMC proteins and
149 another based on the seven serum proteins. Using the test cohort (Cohort 2), the
150 PBMC model achieved an Areas Under the Curve (AUC) score of 0.84, while the
151 serum one of 0.82 (Figure 2A). Next, we developed an ensemble model combining
152 these two models, which led to better performance (AUC = 0.87) (Figure 2A).
153 Five PBMC proteins (UNC45A, IGHM, FADD, NCK2, and DCPS) and seven serum
154 proteins (SERPINA10, SOD3, LTA4H, SPP2, NAGLU, APLP2, and CHRDL2) were
155 selected for our machine learning models. Most of the above PBMC biomarkers are
156 expressed in immune cells, including B cells, macrophages, natural killer (NK) cells,

157 and dendritic cells (HPA; Karlsson et al., 2021). They are thus associated with both
158 innate and adaptive immunity (Figures 2B, 2D). In particular, UNC45A acts as a co-
159 chaperone for HSP90 promoting progesterone receptor function in the cell, and is
160 required for the NK cell cytotoxicity via lytic granule secretion's control (Iizuka et al.,
161 2015). IGHM is the constant region of immunoglobulin heavy chains and mediates
162 the effector phase of humoral immunity, which eliminates the bound antigens. FADD
163 is an adaptor molecule that interacts with various cell surface receptors, mediates
164 cell apoptotic signals, and is essential in early T cell development (Kabra et al.,
165 2001). The seven serum biomarkers are associated with immunity and metabolism
166 (Figures 2C and 2E): SERPINA10 and SPP2 are secreted proteins associated with
167 coagulation and metabolism; LTA4H is enriched in Kupffer cells, monocytes, and
168 neutrophils; NAGLU is mainly expressed in most immune cells; SOD3 and CHRDL2
169 can interact with the extracellular matrix (ECM) organization (HPA; Karlsson et al.,
170 2021).

171 Based on our three models, only two participants from the test cohort (Nos. 209 and
172 233) were mispredicted. Possibly, their predictions were affected by their drug
173 treatments. Specifically, participant No. 209 was incorrectly predicted to be
174 seronegative. This may be due to the long-term treatment with simvastatin and
175 rosuvastatin against hyperlipidemia, which have been suggested to enhance the
176 immune response (Guerra-De-Blas et al., 2019; Karmaus et al., 2019). Participant
177 No. 233, whose atherosclerosis was treated with bisoprolol fumarate before
178 vaccination, was predicted to be seropositive despite being seronegative at D57.
179 Despite these two mispredictions, our results showed that PBMC and serum
180 proteomics could well predict the individual host responses after vaccination.
181 In addition, predicting those being negative at D28 and then converting (Group 1) or
182 never converting (Group 0) could allow for the earlier switch to another vaccine.
183 Similarly, we developed a set of models based on proteins at D0 and achieved an
184 AUC score of 0.843 (PBMC model), 0.847 (serum model) and 0.853 (ensemble
185 model combining these two models) to predict the individual host responses after
186 vaccination (Figures S3A-C).

187 ***Increased innate and adaptive immunity in the seropositive group***

188 We next explored the differences between the seropositive and the seronegative
189 groups using the PBMC data. Thirty-eight proteins were differentially expressed
190 (DEPs) within the PBMC proteome between the two groups at three time points
191 (Benjamini-Hochberg (B-H) adjusted p-value < 0.05, $|\log_2(\text{fold change})| > 0.25$)
192 (Table S3, Figures 3A and 3B). In particular, 33 proteins were dysregulated at D0 or
193 D28. This result suggests that the immune system of the two groups was different at
194 baseline (D0) and was most strongly activated during the early stage after
195 vaccination.

196 A gene-set variation analysis (GSVA) was then used to identify the most significantly
197 enriched pathways in the seropositive and the seronegative groups. The resulting
198 pathways (B-H adjusted p-value < 0.05, $|\log_2(\text{fold change})| > 0.25$) were mainly
199 involved in the immune system. They included the IFN γ , IFN α and IFN β signaling,
200 RNA and DNA modulation, and metabolic pathways. Most of these pathways were
201 upregulated in the seropositive group (Figure 3C).

202 The DEPs among the three immune response groups – Group 0, Group 1, and
203 Group 2 (Figure 1A) – were primarily involved in RNA metabolism, cellular
204 processes, and cytoskeleton regulation-related pathways (Figures S4A-D).
205 Therefore, the dysregulation of these proteins may have contributed to elevated
206 immunity. This agrees with the functional analysis between the seropositive and the
207 seronegative groups. Over 80% of DEPs observed between Group 1 and Group 0
208 were also detected in the comparison between seropositive (Group 1+2) and
209 seronegative (Group 0) groups (Figures S3D, S3E and Table S3).
210 We next analyzed the immune cells composition of the PBMCs in our experiment
211 using the deconvolution algorithm of CIBERSORT (Newman et al., 2015). The
212 seropositive group showed an increase in memory B cells and a reduction of naïve B
213 cells (Figure 3D). In addition, CD8⁺ T cells and activated memory CD4⁺ T cells were
214 significantly higher in the seropositive group than in the seronegative one at D0. The
215 adaptive immune responses were thus significantly enhanced at the baseline in the
216 seropositive group (Figure 3E). At D57, the memory B cells and the CD8⁺ T cells
217 showed an upward trend over time and were significantly higher in the seropositive
218 group. This result is consistent with the reported host responses to SARS-CoV-2
219 infection and vaccination (Chen et al., 2021; Sette and Crotty, 2021). Furthermore,
220 some innate immune cells, such as monocytes, activated NK cells, and activated
221 dendritic cells, also increased over time in the seropositive group (Figure 3E).
222 Moreover, the early seropositive group showed increased memory B cells, activated
223 NK cells, M1 and M2 macrophages (Figures S4F-G). These results show that the
224 proportion of SARS-CoV-2-specific memory lymphocytes may increase after
225 vaccination with CoronaVac[®].

226 ***The interaction between metabolism and immunity is linked with*** 227 ***seroconversion***

228 We next investigated the differences between the seropositive and the seronegative
229 groups using the serum data. A total of 13 DEPs were found at D0 and D28, and two
230 at D57 (B-H adjusted p-value < 0.05, $|\log_2(\text{fold change})| > 0.25$) (Table S3, Figures
231 4A-B). In line with our findings from the PBMC data, more DEPs were identified at D0
232 and D28 than at D57. All the DEPs were upregulated in the seropositive group
233 except TTR. Misfolding and aggregation of TTR, causing amyloid thyroxine protein
234 amyloidosis, has been reported associated with a higher risk of COVID-19 morbidity
235 and mortality (Brannagan et al., 2021). This finding is consistent with our results, as
236 TTR was downregulated in the seropositive group. Many of our serum DEPs are
237 secreted proteins and include components of the immunoglobulin family: IGKV1-8,
238 IGKV1-16, and IGHV3-15 (Schroeder and Cavacini, 2010).
239 Further functional analyses were performed on the DEPs between the seropositive
240 and the seronegative groups, and among the three immune response groups. The
241 significantly enriched functions were neutrophil degranulation, acute phase response
242 signaling, and hemostasis (Figures 4B-C, S5A-B, Table S4). It has been shown that
243 the enriched apolipoprotein family could induce the activation of leukocytes,
244 especially the degranulation of neutrophils (Botham and Wheeler-Jones, 2013). Our
245 analyses showed that 15 out of the 17 proteins involved in plasma lipoprotein

246 remodeling and six out of the eight proteins involved in neutrophil degranulation were
247 upregulated in the seropositive groups (Figure 4C). This finding suggests that the
248 interaction of metabolism and immunity is closely linked with seroconversion.

249 ***Predicting individual antibody persistence to guide booster shot planning***

250 To predict whether the antibodies produced after the CoronaVac[®] vaccination could
251 last for at least 180 days, we generated machine learning models based on the
252 proteomics data and the clinical indicators collected prior to vaccination. In this
253 analysis, we excluded participants from Group 0 (the seronegative ones) and those
254 without clinical indicators on D180. Then the remaining two cohorts (Table 2) were
255 the discovery cohort (Cohort 3, N = 107) and the test cohort (Cohort 4, N = 20).
256 Similar as before, proteins with a significant difference (p-value < 0.05) between two
257 classes and with $|\log_2(\text{fold change})| > 0.25$ in the discovery dataset were included in
258 our final feature set. Then, some proteins (NA rate > 50%) were removed. We
259 optimized the models' parameters in the discovery dataset. An AUC score of 0.79
260 was obtained using only the PBMC proteins (Figure 5A), indicating that PBMC
261 proteomics had an excellent prediction ability of the antibody response after both 57
262 and 180 days.

263 The four PBMC biomarkers (PYCARD, MTMR2, PPCDC, and BRAF) selected by
264 machine learning showed different expression patterns of the immune cells between
265 Groups 3 and 4 (Figure 5C). In particular, PYCARD and PPCDC are mainly
266 expressed in innate immune cells, like monocytes and dendritic cells. MTMR2 and
267 BRAF, on the other hand, are expressed in innate and adaptive immune cells,
268 including NK cells, monocytes, T cells, and B cells (Figure 5D).

269 However, seven participants were incorrectly predicted using this model. Specifically,
270 participants Nos. 209 and 216 were incorrectly classified, probably because they
271 both received simvastatin and rosuvastatin (Guerra-De-Blas et al., 2019; Karmaus et
272 al., 2019). In addition, three participants (Nos. 212, 222, and 225) with fatty liver
273 disease and metabolic abnormalities were also wrongly predicted, probably due to
274 their metabolic conditions. No. 226 was misclassified because of receiving
275 dexamethasone and amoxicillin.

276 **Discussion**

277 ***Predicting the host response to CoronaVac[®] vaccination using a machine*** 278 ***learning model***

279 We conducted a TMT-based proteomics analysis to profile the PBMC and serum
280 features that could affect the response to the CoronaVac[®] vaccination. Using a set of
281 biomarkers measured before vaccination, we built three models to predict individual
282 NAb levels at D57 and another model to predict the persistence of NAbs until at least
283 D180. These potential biomarkers, which were used to distinguish different host
284 responses, were validated using an independent cohort, confirming that the changes
285 in PBMC and serum proteins reflect the pathophysiological differences between
286 seropositive and seronegative subjects.

287 *Potential biomarkers for vaccine-induced antibody generation and persistence*

288 The proteins used by our machine learning classifiers contain several known
289 biomarkers for COVID-19 severity or viral infections. Of note, SERPINA10,
290 predominantly expressed in the liver and subsequently secreted into plasma, inhibits
291 the activity of the coagulation factors Xa and XIa in the presence of protein Z,
292 calcium, and phospholipids (Han et al., 2000). SERPINA10 is a known discriminating
293 feature between severe and non-severe COVID-19 (Shen et al., 2020), and can be
294 used as a classifier of disease severity (Messner et al., 2020). Specifically, it is
295 upregulated in the severe COVID-19 cases. In our data, SERPINA10 was
296 downregulated in the seropositive group with a negative SHapley Additive
297 exPlanations (SHAP) value (Figures 2C and 2E). This result further highlights the
298 role of coagulation during COVID-19 vaccination and indicates that SERPINA10 may
299 contribute to reducing antibody generation. SOD3, an antioxidant enzyme, has been
300 reported to be downregulated in the urine of severe COVID-19 cases (Bi et al.,
301 2021). In our study, SOD3 was significantly upregulated in the seropositive group
302 with a positive SHAP value, indicating that SOD3 may promote antibody generation.
303 PYCARD, a key mediator of apoptosis and inflammation, is mainly involved in the
304 innate immune response (Wang et al., 2017). It also contributes to T-cell immunity
305 stimulation and cytoskeletal rearrangements coupled to chemotaxis and antigen
306 uptake during adaptive immunity (de Souza et al., 2021). We found PYCARD was
307 upregulated in the seropositive group with a positive SHAP value (Figures 5B-C).
308 And thus, we suggest this protein may also promote antibody persistence. These
309 potential biomarkers may promote or reduce antibody generation or persistence,
310 providing therapeutic guidance for vaccination strategy.

311 *Mechanisms behind vaccine-induced immunity*

312 To investigate the molecular mechanisms behind vaccine-induced immunity, we
313 integrated our proteomics analyses and thus generated a summary of the
314 dysregulated pathways between the seropositive and the seronegative groups
315 (Figures 6, S6-7).

316 *Neutrophil degranulation*

317 In our data, we found several proteins involved in activating the neutrophil
318 degranulation-based innate immunity, in particular, LTA4H, LTF, MMP9, TTR, CAP1,
319 PYCARD, and GDI2. Specifically, MMP9, LTF, and CAP1 were upregulated at D28 in
320 the seropositive group. Previous studies have shown that the release of MMP9 from
321 neutrophils stimulates the migration of inflammatory cells and promotes inflammation
322 and the degradation of the alveolar-capillary barrier (Davey et al., 2011). In our
323 seropositive data, MMP9 was upregulated at D28 and then downregulated at D57
324 (Figure 6C). This result suggests MMP9 may contribute to a reduced antibody
325 generation, and is consistent with this protein being an indicator of respiratory failure
326 (Ueland et al., 2020) and enhanced mortality risk in COVID-19 patients (C et al.,
327 2021). Indeed, evidence has shown that neutrophil activation is a hallmark of severe
328 SARS-CoV-2 infection (Meizlish et al., 2021). Therefore, we speculate that a modest
329 upregulation of neutrophil degranulation may contribute to immunity activation and

330 *vice versa.*

331 *Regulation of lymphocyte migration*

332 Most regulators of leukocyte extravasation and lymphocyte migration were elevated
333 at D0 or during the early stages in the seropositive group: MSN, MMP9, CXCL12,
334 FADD, NCK2, and TMSB10. In particular, MSN interacts with members of the ezrin-
335 radixin-moesin family and regulates lymphocyte egress from lymphoid organs
336 (Serrador et al., 1998). TMSB10, CXCL12, and NCK2 regulate the cytoskeleton
337 organization and are involved in transmigration (Figure 6A). By secreting proteases
338 like MMP9, leukocytes degrade the basement membrane and penetrate the tissue
339 interstitial spaces (Sternlicht and Werb, 2001). T-cell receptors are activated through
340 the binding by FADD and the interaction with NCK2, consistently with our immune
341 cell analysis (Figure 6C). Except for antigen recognition, T cell migration was
342 positively regulated by CXCL12, FADD, and PYCARD in our seropositive groups.
343 Intriguingly, increased FADD at baseline possibly contributed to the enhanced
344 antibody generation at D57 (Figure 2D). Also, higher PYCARD at baseline led to a
345 long antibody persistence based on our machine learning models (Figure 5C).

346 *Humoral immune response*

347 The B-cell receptor is a complex of surface immunoglobulin, and some of its
348 accessory molecules, such as IGHM, IGHV3-15, IGKV1-8, and IGKV1-16, were
349 upregulated in our seropositive group (Figure 6C). Following the receptor cross-
350 linking, a complex cascade of signaling molecules results in NF- κ B complex and B-
351 cell receptor activation. These IgG and cytokines are expressed by JCHAIN and LTF,
352 which were both significantly elevated in our data after vaccination. In addition,
353 several of our overlapping proteins' clusters of PBMC and serum were involved in
354 neutrophil degranulation, protein-lipid complex remodeling, platelet degranulation,
355 and complement system (Figures S6-S7). Our data show that the neutrophil
356 degranulation-based activation of the innate immunity, the multiple immune cell
357 migration enhancement, and the humoral immune response activation are
358 dysregulated at baseline and during the early stages after vaccination (Figures 6A-
359 C).

360 ***Comparisons with other studies before/after vaccination***

361 Several studies of COVID-19 vaccination have identified modulation of multiple
362 proteins, metabolites, and gene expression after vaccination (Arunachalam et al.,
363 2021; Liu et al., 2021; Zhang et al., 2021; Wang et al., 2022). However, no study has
364 systematically investigated the heterogeneous hematological host responses to
365 vaccination in both PBMCs and sera. Neither has any study presented any means to
366 predict the host responses of vaccination. Vaccine-induced protection against
367 COVID-19 may involve NAbs, T-cells, and innate immune mechanisms. In the
368 comparative analysis of multiple vaccines, T cell responses in CoronaVac[®] remains
369 unclear (Sadarangani et al., 2021). Our PBMCs analysis showed that CD8⁺ T cells,
370 memory B cells, and activated NK cells were increasingly upregulated in the
371 seropositive group. Previous study showed that mRNA vaccinations can significantly

372 enhance the innate immune response, as proven by the greater frequency CD14⁺
373 CD16⁺ inflammatory monocytes and higher concentration of plasma IFN γ
374 (Arunachalam et al., 2021). In our PBMC proteome, monocytes and the IFN γ , IFN α
375 and IFN β signaling were elevated in the seropositive groups. A single-cell RNA-
376 sequencing study of the PBMCs of healthy subjects revealed that, after CoronaVac[®]
377 vaccination, the levels of B cells, T cells, NK cells, and myeloid cells better
378 resembled those of COVID-19 recovery controls rather than their own before
379 vaccination (Zhang et al., 2021). Similarly, our PBMCs analysis showed that CD8⁺ T
380 cells, memory B cells, and activated NK cells were increasingly upregulated in the
381 seropositive group. Consistent with other reports (Wang et al., 2022), our findings
382 support that the humoral immune response, complement activation were induced by
383 CoronaVac[®]. What's unique in the seropositive participants is activated regulation of
384 lymphocyte migration pathway, which suggests enhanced immunity.

385 ***Planning booster shot and their benefits***

386 Due to the relatively high effectiveness of booster immunization against severe
387 COVID-19, hospitalization, and even the Omicron variant (Xue et al., 2022), it should
388 be strongly supported and administered at the appropriate time. The effectiveness
389 and the safety of boosters have been assessed via large-scale randomized studies
390 and individuals, proving the booster's benefits and the negligible impact of its
391 immune-mediated side effects (Zeng et al., 2021). Boosting is particularly important
392 for specific subpopulations: individuals who generate less or shorter-lived NABs and
393 those who are immunocompromised, such as our seronegative participants (Group
394 0). Moreover, the vaccination strategy may change for recipients with heterologous or
395 homologous vaccinations (Costa Clemens et al., 2022). Our machine learning
396 models predict the seropositivity of individuals at D57 and their NABs persistence
397 until at least D180 using potential blood-derived protein biomarkers. These tools can
398 establish which populations or individuals may generate enough and persistent
399 NABs, and therefore help plan precise booster administrations. Furthermore, a better
400 balance between primary vaccination and booster may benefit more countries in the
401 global fight against COVID-19 (Krause et al., 2021).

402 In summary, we performed a systematic PBMC and serum proteomic study of the
403 heterogeneous hematological host responses to vaccination. We developed a
404 machine learning model based on a panel of proteins expressed at baseline to
405 predict antibody generation and decline after vaccination. The model can be
406 potentially used to identify the individuals of high risk, and guide booster shot, or
407 recommendation of other vaccines. Furthermore, our data also provides a panoramic
408 view of the molecular changes in PBMCs and serum after vaccination.

409 **Limitations of the study**

410 The findings of this study have to be considered in light of some limitations. First, the
411 predictive models need to be further validated in larger cohorts and multicenter
412 samples, both biologically and clinically. Second, the explanations for
413 misclassifications are not very strong, may because of complex drug history. Third,

414 the B cell and T cell responses and the neutralization tests were analyzed in the
415 mixed PBMCs but not assessed *in vitro*.
416

417 **Acknowledgements**

418 This work was supported by the National Natural Science Foundation of China
419 (32200763), Key medical disciplines of Hangzhou, the Medical Health Science and
420 Technology Project of Hangzhou municipal Health Commission (A20210205), the
421 National Key R&D Program of China (2020YFE0202200). The Affiliated Drum
422 Tower Hospital, Medical School of Nanjing University (2022-LCYJ-MS-08). We
423 thank Westlake University Supercomputer Center for assistance in data generation
424 and storage, and the Mass Spectrometry & Metabolomics Core Facility at the
425 Center for Biomedical Research Core Facilities of Westlake University for sample
426 analysis. We gratefully acknowledge Yi Yu for data analysis, Liqin Qian for editing
427 the manuscript.

428 **Data Availability**

429 All mass spectrometry data in this paper are available in the platform iProX at
430 <https://www.iprox.org/>. Project ID: IPX0004305000. All the data will be publicly
431 released upon publication. (URL:
432 <https://www.iprox.cn/page/PSV023.html?url=1666845005314ZrCF;Password:ZACa>)

433 **Author contributions**

434 J.S., T.G., and J.L. designed and supervised the project. Q.Z., Y.S., L.S. collected
435 the samples and clinical data. X.Yi., Y.W., and X.Ye. conducted proteomics
436 analysis. Y.W., R.S., Q.Z., and X.Yi. performed the experimental design and data
437 interpretation. L.H., Y.W., and W.G. analyzed the proteomics data. Y.H. and Y.L.
438 performed machine learning. Q.Z. analyzed the clinical data. Y.W., Q.Z., R.S., Y.H.,
439 H.G., J.L., T.G., and J.S. wrote the manuscript with inputs from co-authors.

440 **Declaration of interest statement**

441 T.G. is a shareholder of Westlake Omics Inc. X.Yi., L.H., Y.H., W.G., X.Ye. and Y.L.
442 are employees of Westlake Omics. The remaining authors declare no competing
443 interests in this paper.

444 **Experimental Procedures**

445 **Experimental Design and Statistical Rationale**

446 The overall goal was systematic investigation of host responses to COVID-19
447 vaccines, including the heterogeneity among the recipients, and machine learning

448 models to predict the effectiveness of vaccination using potential biomarkers at
449 baseline. Subject information for vaccinated recipients is summarized in Tables 1-2,
450 Table S1. Study design of the TMT-Pro labeling-based quantitative proteomics
451 analysis of the PBMCs and sera samples is depicted in Figure 1A and S2A.

452 **Participants and Samples**

453 We recruited 163 vaccination recipients (>18 years) who were not infected with
454 SARS-CoV-2 and some of them had stable chronic medical conditions, including
455 hypertension, T2DM, and metabolic fatty liver disease, were eligible to be enrolled
456 from the affiliated hospital of Hangzhou Normal University between January and
457 February 2021, including a discovery (N = 137) and an independent test cohort (N =
458 26). All participants received two doses of CoronaVac® (0.5 mL/dose, Sinovac life
459 science, Beijing, China), an inactivated vaccine against SARS-CoV-2; the second
460 dose 28 days after the first one. Blood samples were collected before vaccination
461 (D0), then 28 (D28), 57 (D57). Blood mononuclear cells and serum were extracted
462 from the blood samples. The xenoreactivity was also measured at D0, D28, D57 and
463 180 days after the first dose vaccination (D180). The NAb for the receptor-binding
464 domain of the SARS-CoV-2 spike protein were detected using the iFlash 2019-nCoV
465 NAb assay (SHENZHEN YHLO BIOTECH CO., LTD, Shenzhen, China,
466 Cat#C86109), which is a paramagnetic particle chemiluminescent immunoassay for
467 the qualitative detection of SARS-CoV-2 NAb in human serum and plasma using the
468 automated iFlash immunoassay system; the cut-off value for the antibody was 10.00
469 AU/mL.

470 The participants were classified into three groups based on the xenoreactivity of their
471 NAb on D28 and Day 57. Specifically, Group 0 included the participants that were
472 seronegative on D28 and D57; Group 1 included the participants that were
473 seronegative on D28 but were seropositive on D57; Group 2 included the participants
474 that were seropositive on D28 and D57. Groups 1 and 2 were then merged into
475 Group 1+2 (all the seropositive participants). Group 1+2 was then split into Group 3
476 (seronegative at D180) and Group 4 (seropositive at D180).

477 This research was approved by the ethical committee of the Affiliated Hospital of
478 Hangzhou Normal University and Westlake University (Hangzhou, China). The study
479 was registered in the Chinese Clinical Trial Register (ChiCTR2100042717), and all
480 participants signed a written informed consent before enrolment.

481 **Serum and PBMC Protein Extraction and Digestion**

482 From each sample, 4 μ L of serum were depleted of 14 high abundant serum proteins
483 using a human affinity depletion resin (Thermo Fisher Scientific™, San Jose, USA)
484 and then concentrated into 50 μ L through a 3K MWCO filtering unit (Thermo Fisher
485 Scientific™, San Jose, USA). More details can be found in the manufacturer's
486 protocols. The resulting serum samples were then prepared for mass spectrometry
487 as described (Shen et al., 2020). Briefly, they were denatured in 8 M urea at 31.5°C
488 for 30 min. Next, the proteins were reduced with 10 mM tris (2-carboxyethyl)
489 phosphine (TCEP) and then alkylated with 40 mM iodoacetamide (IAA). Finally, the

490 protein extracts were diluted and digested using a double step trypsinization for 16
491 hours totally (Hualishi Tech. Ltd, Beijing, China).

492 PBMCs were prepared as previously described (Gao et al., 2020). Briefly, 30 μ L of
493 lysis buffer in 100 mM TEAB with 20 mM TCEP, and 40 mM IAA were added to the
494 PCT-Microtubes for 60 min. The proteins were digested using a mixture of trypsin
495 and Lys-C for 100 min. Then, the digestion was arrested by adding 10%
496 trifluoroacetic acid (TFA).

497 **LC-MS/MS Analysis**

498 The proteome analysis was performed similar as previously described (Shen et al.,
499 2020). Digested peptides were cleaned-up and labeled using TMTpro 16plex label
500 reagents (Thermo Fisher Scientific, San Jose, USA). Peptides were separated into
501 30 fractions, which were later combined into 15 fractions. Subsequently, the fractions
502 were dried, redissolved in 2% ACN/0.1% formic acid. All the samples were analyzed
503 using liquid chromatography (LC)-coupled tandem mass spectrometry (MS/MS) with
504 a data-dependent acquisition mode on an Orbitrap 480 (Thermo Fisher Scientific,
505 San Jose, USA). During each acquisition, peptides were analyzed using a 30
506 minutes-long LC gradient (from 7% to 30% buffer B). The m/z range of MS1 was
507 375-1800, with a resolution of 60,000, normalized Automatic Gain Control (AGC)
508 target of 300%, maximum ion injection time (max IT) of 50 ms, and compensation
509 voltages of -48V and -68V for FAIMS Pro™. MS/MS experiments were performed
510 with a resolution of 30,000, normalized AGC target of 200%, and 86 ms max IT for
511 Serum and 100 ms for PBMC. The turbo-TMT and the advanced peak determination
512 were enabled.

513 **Database Search for Proteomics Quantification**

514 The mass spectrometric data were analyzed using Proteome Discoverer (Version
515 2.4.0.305, Thermo Fisher Scientific) and the *Homo sapiens* protein database
516 downloaded from UniProtKB on 27 April 2020 (Fasta file containing 20,301 reviewed
517 protein sequences). The database search was performed as previously described
518 (Shen et al., 2020), including Carbamidomethyl (C) as a fixed modification and
519 oxidation (M) as a variable modification. The false discovery rate (FDR) was set as
520 0.01. Data normalization was performed against the total peptide amount. Other
521 parameters followed the default setup.

522 **Quality Control of the Proteome Data**

523 The quality of the proteomics data was ensured at multiple levels. A pool of samples
524 labeled by TMTpro-134N was used as the control for aligning the data from different
525 batches. Also, we assessed the reproducibility of the data using technical replicates,
526 water samples (buffer A) as blanks every four injections to avoid carry-over.
527 After removing the proteins with over 90% missing values, 6331 proteins of PBMC
528 and 961 of serum underwent quality controls. We then assessed the coefficient of
529 variation in the pooled samples (Figure S2B). Finally, the Pearson's correlation

530 values of the technical replicates (17 PBMC samples and three serum samples) were
531 used to evaluate the reproducibility of the data (Figure S2C).

532 **Statistical Analysis of Clinical Indicators**

533 Continuous variables were calculated by student t-test or Welch t-test, Pearson χ^2
534 test or Fisher's exact test for the analysis of categorical outcomes. We calculated
535 Geometric Mean Titers (GMT) of the neutralizing antibody titers and the overall anti-
536 Spike IgG levels, using the t-test method to compare the difference. Statistical
537 analysis was performed by IBM SPSS Statistics 26 (Armonk, NY: IBM Corp).

538 **Differential Expression Analysis**

539 A set of statistical tools were used to process and analyze our proteomics data. First,
540 the batch effect of the serum proteome was removed using the R package combat
541 (<https://lifeinfor.shinyapps.io/batchserver/>). No other significant batch effect was
542 highlighted by principal component analysis (Figures S2D-E). For comparing the
543 protein expressions between groups, the \log_2 (fold change) was calculated using the
544 mean values of each group. A two-sided unpaired Welch's t-test was performed for
545 each group pair. A one-way analysis of variance (ANOVA) was performed among
546 three groups at three time points. Finally, the adjusted p-values were calculated using
547 the B-H correction.

548 DEPs were selected by imposing the B-H adjusted p-values to be less than 0.05 and
549 the absolute \log_2 (fold change) larger than 0.25. Next, a soft clustering of the time
550 series data was performed using MFuzz (version 2.48.0). We clustered the PBMC
551 and serum DEPs expression along time using default settings (Figure S6). The
552 single-cell RNA expression of PBMCs was derived from the Human Proteins Atlas
553 (HPA; Karlsson et al., 2021).

554 **Estimation of the Immune Cell Type Fractions**

555 CIBERSORT (<https://cibersort.stanford.edu/>) is an analytical tool for estimating the
556 cell composition of tissues using their gene expression profiles (Newman et al.,
557 2015). In CIBERSORT, the relative amounts of 20 human immune cell types
558 (including naïve and memory B cells, seven T cell types, NK cells, plasma cells,
559 monocytes, etc.) were estimated in our PBMC bulk cells using the leukocyte gene
560 signature matrix. In addition, vaccinated individuals were divided into seronegative
561 and seropositive groups, and the fraction of each immune cell type was investigated
562 and visualized with bar plots using R software (R 4.0.5).

563 **Machine Learning**

564 For prediction of NABs generation on D57, we used the samples from a discovery
565 cohort (Cohort 1, N = 137) to optimize the model's parameters, the discovery dataset
566 was randomly split into a training (80%) and a validation (20%) dataset. To establish
567 the features for our machine learning models, we used a differential protein
568 expression analysis which returned a set of biomarkers from the PBMCs and the
569 serum (Figure 2A and 5A). Proteins with a significant difference (p-value < 0.05)

570 between two classes and with $|\log_2(\text{fold change})| > 0.25$ in the training dataset were
571 included in our final feature set. Then, sparse proteins (NA rate > 50%) were
572 removed. The missing values were imputed with the minimum of each protein. We
573 decided on the top N best features as the final feature set for our model, as well as
574 the optimal parameters, by searching for the highest AUC in the validation dataset.
575 All individual models for these two tasks can achieve an AUC of 1.0 in the validation
576 dataset. Finally, the results illustrated in this paper were derived from the model with
577 the best features and parameters. The implementation of machine learning was done
578 using Python 3.8.10 and xgboost 1.4.2 python package (Chen and Guestrin,
579 2016). The model was then tested using an independent test cohort (Cohort 2, N =
580 26): the first based on PBMC biomarkers and the second on serum biomarkers. We
581 next developed a third model that was an ensemble of the two previous ones. This
582 third model led to an AUC of 0.87, which was higher than using PBMC or serum
583 proteins individually.
584 For prediction of NAbs persistence till D180, we discarded participants from Group 0
585 (the seronegative ones) and those without clinical indicators on D180, and the
586 remaining two cohorts: a training cohort (Cohort 3, N = 107) and a test cohort for the
587 validation (Cohort 4, N = 20). We optimized the models' parameters in the training
588 and a validation dataset. Similarly, we tested in Cohort 4, and an AUC score of 0.79
589 was obtained using only the PBMC proteins (Figure 5A).

590 **Functional Analyses**

591 Specifically, we investigated 38 PBMC DEPs and 14 serum DEPs from different
592 immune response groups using a two-sided unpaired Welch's t-test, and 985 DEPs
593 from PBMCs and 129 DEPs from serum were evaluated using the ANOVA test,
594 biomarker proteins were also included. Several pathway analysis tools were used to
595 perform the functional analysis of our significantly DEPs. Enrichments analyses
596 based on Gene Ontology processes, KEGG pathways, Reactome gene sets, and
597 Wiki pathways were performed using the web-based platform of Metascape (Zhou et
598 al., 2019). With an ingenuine pathway analysis (Kramer et al., 2014) of the regulated
599 proteins, we identified the most significantly regulated pathways; p-values were
600 based on a right-tailed Fisher's Exact Test, and the enriched pathways' overall
601 activation/inhibition state was predicted using the z-score. A pathway's regulation
602 was significant if its p-value < 0.05. Gene Set Variation Analysis (GSVA) was
603 performed using the R package GSVA (version 3.11) (Hanzelmann et al., 2013) to
604 identify the most dysregulated pathways (Canonical pathways) between the
605 seronegative and the seropositive groups (B-H adjusted p-value < 0.05). The
606 functional network images generated by Metascape were visualized with Cytoscape
607 (version 3.9.0) to generate the network of predicted associations for a specific group
608 of proteins (Otasek et al., 2019).
609

610 References

- 611 Ai, J., Guo, J., Zhang, H., Zhang, Y., Yang, H., Lin, K., Song, J., Fu, Z., Fan, M., Zhang, Q., *et al.*
612 (2022). Cellular basis of enhanced humoral immunity to SARS-CoV-2 upon homologous or
613 heterologous booster vaccination analyzed by single-cell immune profiling. *Cell Discovery* 8.
614 Arunachalam, P.S., Scott, M.K.D., Hagan, T., Li, C., Feng, Y., Wimmers, F., Grigoryan, L., Trisal, M.,
615 Edara, V.V., Lai, L., *et al.* (2021). Systems vaccinology of the BNT162b2 mRNA vaccine in humans.
616 *Nature* 596, 410-416.
617 Bi, X., Liu, W., Ding, X., Liang, S., Zheng, Y., Zhu, X., Quan, S., Yi, X., Xiang, N., Du, J., *et al.* (2021).
618 Proteomic and metabolomic profiling of urine uncovers immune responses in patients with
619 COVID-19. *Cell Rep*, 110271.
620 Botham, K.M., and Wheeler-Jones, C.P. (2013). Postprandial lipoproteins and the molecular
621 regulation of vascular homeostasis. *Prog Lipid Res* 52, 446-464.
622 Brannagan, T.H., 3rd, Auer-Grumbach, M., Berk, J.L., Briani, C., Bril, V., Coelho, T., Damy, T.,
623 Dispenzieri, A., Drachman, B.M., Fine, N., *et al.* (2021). ATTR amyloidosis during the COVID-19
624 pandemic: insights from a global medical roundtable. *Orphanet J Rare Dis* 16, 204.
625 C, D.A.-M., Couto, A.E.S., Campos, L.C.B., Vasconcelos, T.F., Michelon-Barbosa, J., Corsi, C.A.C.,
626 Mestriner, F., Petroski-Moraes, B.C., Garbellini-Diab, M.J., Couto, D.M.S., *et al.* (2021). MMP-2
627 and MMP-9 levels in plasma are altered and associated with mortality in COVID-19 patients.
628 *Biomed Pharmacother* 142, 112067.
629 Chen, T.Q., and Guestrin, C. (2016). XGBoost: A Scalable Tree Boosting System. *Kdd'16:*
630 *Proceedings of the 22nd Acm Sigkdd International Conference on Knowledge Discovery and*
631 *Data Mining*, 785-794.
632 Chen, Y., Yin, S., Tong, X., Tao, Y., Ni, J., Pan, J., Li, M., Wan, Y., Mao, M., Xiong, Y., *et al.* (2021).
633 Dynamic SARS-CoV-2 specific B cell and T cell responses following immunization of an
634 inactivated COVID-19 vaccine. *Clinical microbiology and infection : the official publication of the*
635 *European Society of Clinical Microbiology and Infectious Diseases*.
636 Costa Clemens, S.A., Weckx, L., Clemens, R., Almeida Mendes, A.V., Ramos Souza, A., Silveira,
637 M.B.V., da Guarda, S.N.F., de Nobrega, M.M., de Moraes Pinto, M.I., Gonzalez, I.G.S., *et al.* (2022).
638 Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two
639 doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single
640 blind, randomised study. *The Lancet*.
641 Davey, A., McAuley, D.F., and O'Kane, C.M. (2011). Matrix metalloproteinases in acute lung injury:
642 mediators of injury and drivers of repair. *Eur Respir J* 38, 959-970.
643 de Souza, J.G., Starobinas, N., and Ibanez, O.C.M. (2021). Unknown/enigmatic functions of
644 extracellular ASC. *Immunology* 163, 377-388.
645 Falsey, A.R., Frenck, R.W., Jr., Walsh, E.E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Bailey,
646 R., Swanson, K.A., Xu, X., *et al.* (2021). SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose
647 3. *N Engl J Med* 385, 1627-1629.
648 Gao, H., Zhang, F., Liang, S., Zhang, Q., Lyu, M., Qian, L., Liu, W., Ge, W., Chen, C., Yi, X., *et al.*
649 (2020). Accelerated Lysis and Proteolytic Digestion of Biopsy-Level Fresh-Frozen and FFPE Tissue
650 Samples Using Pressure Cycling Technology. *J Proteome Res* 19, 1982-1990.
651 Guerra-De-Blas, P.D.C., Bobadilla-Del-Valle, M., Sada-Ovalle, I., Estrada-Garcia, I., Torres-

652 Gonzalez, P., Lopez-Saavedra, A., Guzman-Beltran, S., Ponce-de-Leon, A., and Sifuentes-
653 Osornio, J. (2019). Simvastatin Enhances the Immune Response Against Mycobacterium
654 tuberculosis. *Front Microbiol* 10, 2097.
655 Han, X., Fiehler, R., and Broze, G.J., Jr. (2000). Characterization of the protein Z-dependent
656 protease inhibitor. *Blood* 96, 3049-3055.
657 Hanzelmann, S., Castelo, R., and Guinney, J. (2013). GSEA: gene set variation analysis for
658 microarray and RNA-seq data. *BMC Bioinformatics* 14, 7.
659 HPA. Human Protein Atlas, pp. <https://www.proteinatlas.org/>.
660 Iizuka, Y., Cichocki, F., Sieben, A., Sforza, F., Karim, R., Coughlin, K., Isaksson Vogel, R., Gavioli, R.,
661 McCullar, V., Lenvik, T., *et al.* (2015). UNC-45A Is a Nonmuscle Myosin IIA Chaperone Required
662 for NK Cell Cytotoxicity via Control of Lytic Granule Secretion. *J Immunol* 195, 4760-4770.
663 Kabra, N.H., Kang, C., Hsing, L.C., Zhang, J., and Winoto, A. (2001). T cell-specific FADD-deficient
664 mice: FADD is required for early T cell development. *Proc Natl Acad Sci U S A* 98, 6307-6312.
665 Karlsson, M., Zhang, C., Mear, L., Zhong, W., Digre, A., Katona, B., Sjostedt, E., Butler, L., Odeberg,
666 J., Dusart, P., *et al.* (2021). A single-cell type transcriptomics map of human tissues. *Sci Adv* 7.
667 Karmaus, P.W., Shi, M., Perl, S., Biancotto, A., Candia, J., Cheung, F., Kotliarov, Y., Young, N.,
668 Fessler, M.B., and Consortium, C.H.I. (2019). Effects of rosuvastatin on the immune system in
669 healthy volunteers with normal serum cholesterol. *JCI Insight* 4.
670 Kramer, A., Green, J., Pollard, J., Jr., and Tugendreich, S. (2014). Causal analysis approaches in
671 Ingenuity Pathway Analysis. *Bioinformatics* 30, 523-530.
672 Krause, P.R., Fleming, T.R., Peto, R., Longini, I.M., Figueroa, J.P., Sterne, J.A.C., Cravioto, A., Rees,
673 H., Higgins, J.P.T., Boutron, I., *et al.* (2021). Considerations in boosting COVID-19 vaccine
674 immune responses. *Lancet* 398, 1377-1380.
675 Lee, A., Wong, S.Y., Chai, L.Y.A., Lee, S.C., Lee, M.X., Muthiah, M.D., Tay, S.H., Teo, C.B., Tan, B.K.J.,
676 Chan, Y.H., *et al.* (2022). Efficacy of covid-19 vaccines in immunocompromised patients:
677 systematic review and meta-analysis. *BMJ* 376, e068632.
678 Liu, J., Wang, J., Xu, J., Xia, H., Wang, Y., Zhang, C., Chen, W., Zhang, H., Liu, Q., Zhu, R., *et al.*
679 (2021). Comprehensive investigations revealed consistent pathophysiological alterations after
680 vaccination with COVID-19 vaccines. *Cell Discov* 7, 99.
681 Meizlish, M.L., Pine, A.B., Bishai, J.D., Goshua, G., Nadelmann, E.R., Simonov, M., Chang, C.H.,
682 Zhang, H., Shallow, M., Bahel, P., *et al.* (2021). A neutrophil activation signature predicts critical
683 illness and mortality in COVID-19. *Blood advances* 5, 1164-1177.
684 Messner, C.B., Demichev, V., Wendisch, D., Michalick, L., White, M., Freiwald, A., Textoris-Taube,
685 K., Vernardis, S.I., Egger, A.-S., Kreidl, M., *et al.* (2020). Ultra-High-Throughput Clinical
686 Proteomics Reveals Classifiers of COVID-19 Infection. *Cell Systems* 11, 11-24.e14.
687 Newman, A.M., Liu, C.L., Green, M.R., Gentles, A.J., Feng, W., Xu, Y., Hoang, C.D., Diehn, M., and
688 Alizadeh, A.A. (2015). Robust enumeration of cell subsets from tissue expression profiles. *Nat*
689 *Methods* 12, 453-457.
690 Otasek, D., Morris, J.H., Boucas, J., Pico, A.R., and Demchak, B. (2019). Cytoscape Automation:
691 empowering workflow-based network analysis. *Genome Biol* 20, 185.
692 Sadarangani, M., Marchant, A., and Kollmann, T.R. (2021). Immunological mechanisms of
693 vaccine-induced protection against COVID-19 in humans. *Nature Reviews Immunology* 21,
694 475-484.

695 Schroeder, H.W., Jr., and Cavacini, L. (2010). Structure and function of immunoglobulins. *J Allergy*
696 *Clin Immunol* 125, S41-52.

697 Serrador, J.M., Nieto, M., Alonso-Lebrero, J.L., del Pozo, M.A., Calvo, J., Furthmayr, H., Schwartz-
698 Albiez, R., Lozano, F., Gonzalez-Amaro, R., Sanchez-Mateos, P., *et al.* (1998). CD43 interacts with
699 moesin and ezrin and regulates its redistribution to the uropods of T lymphocytes at the cell-cell
700 contacts. *Blood* 91, 4632-4644.

701 Sette, A., and Crotty, S. (2021). Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell* 184,
702 861-880.

703 Shen, B., Yi, X., Sun, Y., Bi, X., Du, J., Zhang, C., Quan, S., Zhang, F., Sun, R., Qian, L., *et al.* (2020).
704 Proteomic and Metabolomic Characterization of COVID-19 Patient Sera. *Cell* 182, 59-72 e15.

705 Sternlicht, M.D., and Werb, Z. (2001). How matrix metalloproteinases regulate cell behavior.
706 *Annu Rev Cell Dev Biol* 17, 463-516.

707 Ueland, T., Holter, J.C., Holtén, A.R., Müller, K.E., Lind, A., Bekken, G.K., Dudman, S., Aukrust, P.,
708 Dyrhol-Riise, A.M., and Heggelund, L. (2020). Distinct and early increase in circulating MMP-9 in
709 COVID-19 patients with respiratory failure. *J Infect* 81, e41-e43.

710 van der Graaf, R., Browne, J.L., and Baidjoe, A.Y. (2022). Vaccine equity: past, present and future.
711 *Cell Reports Medicine*.

712 Wang, Y., Ning, X., Gao, P., Wu, S., Sha, M., Lv, M., Zhou, X., Gao, J., Fang, R., Meng, G., *et al.*
713 (2017). Inflammasome Activation Triggers Caspase-1-Mediated Cleavage of cGAS to Regulate
714 Responses to DNA Virus Infection. *Immunity* 46, 393-404.

715 Wang, Y., Wang, X., Luu, L.D.W., Chen, S., Jin, F., Wang, S., Huang, X., Wang, L., Zhou, X., Chen, X.,
716 *et al.* (2022). Proteomic and Metabolomic Signatures Associated With the Immune Response in
717 Healthy Individuals Immunized With an Inactivated SARS-CoV-2 Vaccine. *Front Immunol* 13,
718 848961.

719 WHO (2022-10-25). WHO Coronavirus (COVID-19) Dashboard.

720 Xue, J.-b., Lai, D.-y., Jiang, H.-w., Qi, H., Guo, S.-j., Zhu, Y.-s., Xu, H., Zhou, J., and Tao, S.-c.
721 (2022). Landscape of the RBD-specific IgG, IgM, and IgA responses triggered by the inactivated
722 virus vaccine against the Omicron variant. *Cell Discovery* 8.

723 Zeng, G., Wu, Q., Pan, H., Li, M., Yang, J., Wang, L., Wu, Z., Jiang, D., Deng, X., Chu, K., *et al.*
724 (2021). Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a
725 two-dose schedule, in healthy adults: interim results from two single-centre, double-blind,
726 randomised, placebo-controlled phase 2 clinical trials. *Lancet Infect Dis*.

727 Zhang, H., Hu, Y., Jiang, Z., Shi, N., Lin, H., Liu, Y., Wang, H., Feng, Y., Meng, X., Zhang, S., *et al.*
728 (2021). Single-Cell Sequencing and Immune Function Assays of Peripheral Blood Samples
729 Demonstrate Positive Responses of an Inactivated SARS-CoV-2 Vaccine.

730 Zhao, X., Li, D., Ruan, W., Chen, Z., Zhang, R., Zheng, A., Qiao, S., Zheng, X., Zhao, Y., Dai, L., *et al.*
731 (2022). Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant. *N Engl J*
732 *Med*.

733 Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A.H., Tanaseichuk, O., Benner, C., and
734 Chanda, S.K. (2019). Metascape provides a biologist-oriented resource for the analysis of
735 systems-level datasets. *Nat Commun* 10, 1523.

736 **Tables**

737 Table 1. Clinical metadata of the subjects for Group 0 and Group 1+2.

738 Table 2. Clinical metadata of the subjects for Group 3 and Group 4.

739 **Table 1. Clinical metadata of the subjects for Group 0 and Group 1+2.**

Characteristics	Discovery cohort (Cohort 1, N = 137)	Test cohort (Cohort 2, N = 26)	p	Discovery cohort			Test cohort		
				Group 0 (N = 14)	Group 1+2 (N = 123)	p	Group 0 (N = 5)	Group 1+2 (N = 21)	p
Age (years)	38.839 (11.806)	41.615 (8.782)	0.171	44.643 (12.258)	38.179 (11.622)	0.052	51.800 (5.495)	39.191 (7.633)	0.002
Sex (male/female)	43/94	16/10	0.141	6/8	37/86	0.329	5/0	11/10	0.123
Body mass index (kg/m ²)	24.026 (3.770)	25.314 (3.138)	0.104	26.002 (4.465)	23.801 (3.636)	0.064	26.208 (4.955)	25.097 (2.676)	0.650
Total bilirubin (µmol/L)	19.883 (6.726)	19.285 (5.663)	0.671	19.650 (5.490)	19.909 (6.871)	0.892	20.080 (6.058)	19.095 (5.706)	0.734
Albumin (g/L)	48.457 (2.302)	47.015 (2.706)	0.005	47.979 (2.555)	48.511 (2.277)	0.414	45.820 (1.587)	47.300 (2.865)	0.281
Alanine aminotransferase (U/L)	20.479 (18.397)	20.704 (10.932)	0.952	17.607 (8.737)	20.806 (19.186)	0.540	19.840 (12.213)	20.910 (10.923)	0.849
Aspartate aminotransferase (U/L)	20.410 (9.150)	22.054 (5.075)	0.375	18.693 (5.496)	20.606 (9.473)	0.461	23.620 (6.460)	21.681 (4.806)	0.454
Alkaline phosphatase (U/L)	66.730 (20.253)	69.462 (17.775)	0.522	67.929 (19.828)	66.594 (20.376)	0.816	72.200 (12.696)	68.810 (18.983)	0.710
γ-glutamyl transpeptidase (U/L)	24.854 (21.930)	22.692 (12.142)	0.626	19.714 (10.542)	25.439 (22.823)	0.357	21.600 (7.956)	22.952 (13.086)	0.828
LDL-cholesterol (mmol/L)	3.118 (0.779)	3.106 (0.883)	0.941	2.796 (0.705)	3.155 (0.782)	0.102	3.264 (0.108)	3.068 (0.982)	0.665
HDL-cholesterol (mmol/L)	1.372 (0.326)	1.220 (0.268)	0.026	1.266 (0.182)	1.384 (0.337)	0.092	1.284 (0.163)	1.205 (0.288)	0.563
Total cholesterol (mmol/L)	4.965 (0.966)	4.860 (0.983)	0.611	4.557 (0.928)	5.012 (0.963)	0.103	4.984 (0.172)	4.830 (1.094)	0.760
Triglyceride (mmol/L)	1.017 (0.566)	1.174 (0.645)	0.207	1.089 (0.603)	1.009 (0.564)	0.618	0.962 (0.263)	1.225 (0.701)	0.424
Glucose (mmol/L)	4.146 (1.141)	3.502 (0.826)	0.007	4.210 (1.096)	4.138 (1.150)	0.825	3.398 (1.092)	3.526 (0.782)	0.762
Creatinine (µmol/L)	60.307 (29.087)	67.923 (13.702)	0.194	57.786 (17.375)	60.594 (30.169)	0.607	75.800 (13.046)	66.048 (13.47)	0.157
Uric Acid (µmol/L)	307.839 (95.341)	343.385 (83.196)	0.078	309.286 (52.889)	307.675 (99.170)	0.952	384.400 (75.075)	333.619 (83.690)	0.227
CRP (mg/L)	1.407 (3.782)	1.206 (1.341)	0.790	1.180 (1.460)	1.442 (3.979)	0.808	1.624 (1.984)	1.235 (1.239)	0.579

Leukocytes (10 ⁹ /L)	6.203 (1.453)	6.692 (1.517)	0.120	2.164 (0.674)	2.063 (0.591)	0.594	6.320 (1.659)	6.781 (1.511)	0.552
Platelets (10 ⁹ /L)	247.796 (57.838)	271.500 (59.567)	0.058	245.143 (62.954)	248.098 (57.496)	0.857	227.200 (53.742)	282.048 (57.010)	0.063
Red blood cells (10 ⁹ /L)	6.203 (1.453)	6.692 (1.517)	0.120	4.742 (0.452)	4.732 (0.630)	0.953	5.320 (0.409)	5.043 (0.605)	0.344
Lymphocytes (10 ⁹ /L)	2.074 (0.598)	2.323 (0.513)	0.048	2.164 (0.674)	2.063 (0.591)	0.552	2.060 (0.541)	2.386 (0.499)	0.209
hemoglobin (g/L)	140.985 (19.497)	150.039 (20.166)	0.032	138.143 (22.408)	141.309 (19.215)	0.567	160.800 (13.608)	147.476 (20.868)	0.190
Comorbidities, N (%)									
Hypertension	13 (9)	6 (23)	0.005	1 (7)	12 (10)	0.092	2 (40)	4 (19)	0.558
T2DM	5 (4)	0 (0)	>0.999	1 (7)	4 (3)	0.426	0 (0)	0 (0)	>0.999
MAFLD	37 (27)	13 (50)	0.020	7 (50)	30 (24)	0.005	2 (40)	11 (52)	>0.999
Seroconversion of neutralizing antibody to live SARS-CoV-2, N (%)									
Day 28	30 (22)	2 (7)	0.112	0 (0)	30 (25)	0.040	0 (0)	2 (10)	>0.999
Day 57	123 (90)	21 (81)	0.189	0 (0)	123 (100)	>0.999	0 (0)	21 (100)	<0.001
Day 180	30 (25) ^a	12 (48) ^b	0.021	0 (0) ^c	30 (28) ^d	>0.999	0 (0) ^e	12 (60) ^f	0.043
GMT of neutralizing antibody to live SARS-CoV-2 (AU/mL)									
Day 28	8.523 (5.368)	6.789 (2.781)	0.018	4.817 (1.185)	8.945 (5.497)	<0.001	4.658 (1.379)	7.296 (2.807)	.055
Day 57	27.372 (28.155)	23.309 (19.138)	0.482	7.746 (1.293)	29.606 (28.884)	<0.001	7.948 (1.64)	26.967 (19.602)	.043
Day 180	8.627 (4.315)	10.795 (4.325)	0.024	6.055 (1.976)	8.94 (4.422)	<0.001	6.842 (0.343)	11.784 (4.297)	<0.001

740 Data are shown as mean values (standard deviation within parentheses) and N (%). Pearson χ^2 test or Fisher's exact test were used to analyze the
741 categorical outcomes and student t-test or Welch t-test for continuous outcomes. Hypertension was defined as systolic blood pressure ≥ 140 or
742 diastolic blood pressure ≥ 90 mmHg. T2DM: Type 2 diabetes mellitus, which was defined as fasting glucose ≥ 7.0 mmol/L. MALFD: metabolic
743 associated fatty liver disease. Superscripts a, b, c, d, e, and f: subjects left in each group were 120, 25, 13, 107, 5, and 20, respectively. Group 0, the
744 seronegative group, included the participants that were seronegative on D28 and D57. Groups 1+2 were all the seropositive participants on D57.

745 **Table 2. Clinical metadata of the subjects for Group 3 and Group 4.**

Characteristics	Discovery cohort (Cohort 3, N = 107)	Test cohort (Cohort 4, N = 20)	p	Discovery cohort		Test cohort			
				Group 3 (N = 77)	Group 4 (N = 30)	p	Group 3 (N = 8)	Group 4 (N = 12)	p
Age (years)	40.019 (10.814)	39.950 (6.970)	0.971	40.130 (10.598)	39.733 (11.531)	0.866	40.625 (6.278)	39.500 (7.634)	0.734
Sex (male/female)	32/75	10/10	0.023	20/57	12/18	0.155	2/6	8/4	0.170
Body mass index (kg/m ²)	23.965 (3.746)	25.260 (2.638)	0.142	23.879 (3.660)	24.186 (4.014)	0.705	26.738 (1.701)	24.275 (2.745)	0.037
Total bilirubin (µmol/L)	20.114 (7.080)	18.735 (5.604)	0.412	20.705 (6.615)	18.597 (8.075)	0.167	20.913 (6.399)	17.283 (4.736)	0.161
Albumin (g/L)	48.492 (2.245)	47.175 (2.88)	0.023	48.239 (2.191)	49.140 (2.289)	0.062	46.200 (2.183)	47.825 (3.184)	0.226
Alanine aminotransferase (U/L)	21.114 (19.713)	21.310 (11.048)	0.966	18.468 (16.533)	27.907 (25.255)	0.066	19.350 (12.294)	22.617 (10.487)	0.532
Aspartate aminotransferase (U/L)	20.425 (9.418)	21.555 (4.895)	0.602	19.136 (7.126)	23.733 (13.243)	0.08	20.738 (4.525)	22.100 (5.248)	0.556
Alkaline phosphatase (U/L)	66.720 (21.280)	69.000 (19.456)	0.657	66.065 (22.940)	68.400 (16.492)	0.612	59.875 (15.524)	75.083 (19.988)	0.087
γ-glutamyl transpeptidase (U/L)	26.178 (23.377)	23.3 (13.326)	0.595	24.208 (19.513)	31.233 (31.030)	0.164	18.375 (8.123)	26.583 (15.341)	0.184
LDL-cholesterol (mmol/L)	3.160 (0.800)	3.076 (1.007)	0.680	3.097 (0.769)	3.320 (0.867)	0.196	2.605 (0.655)	3.389 (1.100)	0.088
HDL-cholesterol (mmol/L)	1.370 (0.337)	1.179 (0.27)	0.018	1.406 (0.353)	1.278 (0.276)	0.076	1.188 (0.332)	1.173 (0.235)	0.912
Total cholesterol (mmol/L)	4.996 (0.935)	4.821 (1.122)	0.458	4.907 (0.910)	5.223 (0.973)	0.116	4.316 (0.698)	5.157 (1.247)	0.102
Triglyceride (mmol/L)	1.025 (0.596)	1.245 (0.713)	0.145	0.888 (0.451)	1.375 (0.768)	0.002	1.154 (0.657)	1.305 (0.771)	0.655
Glucose (mmol/L)	4.181 (1.222)	3.593 (0.738)	0.040	4.229 (1.275)	4.060 (1.082)	0.524	3.405 (0.708)	3.718 (0.762)	0.367
Creatinine (µmol/L)	60.009 (31.812)	65.55 (13.621)	0.446	59.610 (37.004)	61.033 (10.440)	0.836	63.000 (10.637)	67.250 (15.51)	0.509
Uric Acid (µmol/L)	301.122 (100.483)	331.650 (85.363)	0.205	288.299 (93.366)	334.033 (111.819)	0.034	349.000 (91.377)	320.083 (83.115)	0.473

CRP (mg/L)	1.224 (2.529)	1.136 (1.209)	0.879	1.270 (2.904)	1.106 (1.151)	0.764	1.084 (0.997)	1.170 (1.374)	0.881
Leukocytes (10 ⁹ /L)	6.173 (1.516)	6.815 (1.542)	0.085	6.012 (1.424)	6.587 (1.685)	0.078	6.500 (1.009)	7.025 (1.828)	0.471
Platelets (10 ⁹ /L)	245.738 (60.240)	287.100 (53.450)	0.005	242.351 (60.909)	254.433 (58.591)	0.354	276.500 (53.407)	294.167 (54.621)	0.484
Red blood cells (10 ⁹ /L)	4.719 (0.654)	5.020 (0.611)	0.059	4.631 (0.679)	4.943 (0.533)	0.026	4.675 (0.534)	5.25 0(0.565)	0.035
Lymphocytes (10 ⁹ /L)	2.026 (0.577)	2.395 (0.510)	0.009	1.949 (0.544)	2.223 (0.622)	0.027	2.188 (0.491)	2.533 (0.494)	0.142
hemoglobin (g/L)	141.037 (20.188)	146.600 (21.01)	0.263	138.558 (21.516)	147.400 (14.776)	0.041	143.375 (14.956)	148.750 (24.647)	0.589
Comorbidity, N (%)									
Hypertension	12 (12)	4 (20)	0.280	8 (11)	4 (14)	0.736	0 (0)	4 (34)	0.094
T2DM	4 (4)	0 (0)	>0.999	3 (4)	1 (4)	>0.999	0 (0)	0 (0)	>0.999
MAFLD	30 (28)	11 (55)	0.018	17 (22)	13 (43)	0.028	5 (63)	6 (50)	0.670
Seroconversion of neutralizing antibody to live SARS-CoV-2, N (%)									
Day 28	26 (25)	2 (10)	0.240	16 (21)	10 (34)	0.174	0 (0)	2 (17)	0.475
Day 57	107 (100)	20 (100)	>0.999	77 (100)	30 (100)	>0.999	8 (100)	12 (100)	>0.999
Day 180	30 (29)	11 (55)	0.018	0 (0)	30 (100)	<0.001	0 (0)	12 (100)	<0.001
GMT of neutralizing antibody to live SARS-CoV-2 (AU/mL)									
Day 28	9.033 (5.837)	7.41 (2.83)	0.023	8.034 (4.35)	11.596 (8.092)	0.028	6.0563 (1.07254)	8.3125 (3.29792)	0.045
Day 57	29.925 (30.425)	27.133 (20.096)	0.694	24.596 (27.2)	43.603 (34.288)	0.009	15.695 (6.17745)	34.7583 (22.6869)	0.034
Day 180	8.94 (4.422)	11.784 (4.297)	0.009	6.905 (1.641)	14.162 (5.021)	<0.001	8.475 (0.68498)	13.9892 (4.28151)	0.001

746 Data are shown as mean values (standard deviation in parentheses). Pearson χ^2 test or Fisher's exact test were used to analyze the categorical
747 outcomes and student t-test or Welch t-test for continuous outcomes. Hypertension was defined as systolic blood pressure ≥ 140 or diastolic blood
748 pressure ≥ 90 mmHg. T2DM: Type 2 diabetes mellitus, which was defined as fasting glucose ≥ 7.0 mmol/L. MALFD: metabolic associated fatty liver
749 disease. Group 3: the group that became seronegative before D180; Group 4: the group that was seropositive at least until D180.

750 Figure legends

751 **Figure 1. Study design and overview of clinical indicators. (A)** Study design of
752 the TMT labeling-based quantitative proteomics analysis of the PBMCs and sera
753 samples. Vaccination recipients were vaccinated with two doses of 500 μ l
754 CoronaVac[®], the first at D0 and the second at D28. Blood samples and PBMCs were
755 collected at D0 (before vaccination), D28, and D57. Participants were divided into
756 four groups based on the xenoreactivity of their NABs on D28 and D57: Group 0, the
757 seronegative group, included the participants that were seronegative on D28 and
758 D57; Group 1, the late seropositive group, included the participants that were
759 seronegative on Day 28 but seropositive on D57; Group 2, the early seropositive
760 group, included the participants that were seropositive on D28 and D57. Groups 1
761 and 2 were combined into Group 1+2 to bring together all the seropositive
762 participants. Group 1+2 was then divided into Group 3 (seronegative participants on
763 D180) and Group 4 (seropositive participants on D180). **(B-C)** Antibody titers of
764 neutralizing antibodies **(B)** and Spike-specific IgG **(C)** to live SARS-CoV-2 at different
765 time points after vaccination. The horizontal line represents the threshold of specific
766 response. The bars represent the median and IQR values of titers. Sample
767 comparisons were tested by student t-test or Welch t-test. * Represents $p < 0.05$, **
768 represents $p < 0.01$, *** represents $p < 0.001$.

769 **Figure 2. Machine learning-based prediction of individuals' seronegative or**
770 **seropositive status based on their PBMCs and serum proteins before**
771 **vaccination. (A)** Our machine learning-based predictor was based on PBMC, serum,
772 and both types of proteins. We used the samples from a discovery cohort (Cohort 1,
773 $N = 137$) to optimize the model's parameters, the discovery dataset was randomly
774 split into a training (80%) and a validation (20%) dataset. The model was then tested
775 using a test cohort (Cohort 2, $N = 26$): the first based on PBMC biomarkers and the
776 second on serum biomarkers. We next developed a third model that was an
777 ensemble of the two previous ones. This third model led to an AUC of 0.87, which
778 was higher than using PBMC or serum proteins individually. **(B)** The SHAP values of
779 the five PBMC proteins were prioritized using the machine learning model. **(C)** The
780 SHAP values of the seven serum proteins were prioritized using the machine
781 learning model. **(D)** Boxplots of the selected biomarker proteins from the PBMC
782 samples. **(E)** Boxplots of the selected biomarker proteins from the serum samples.
783 Asterisks in **(D)** and **(E)** indicate the statistical significance based on the unpaired
784 two-sided Welch's t-test. Specifically, the p-values are: *, < 0.05 ; **, < 0.01 ; ***, $<$
785 0.001 . Group 0: the seronegative group; Group 1+2: the seropositive group.

786 **Figure 3. Comparison of the immune responses in the seropositive and the**
787 **seronegative groups using the PBMCs proteome. (A)** Identification of NAb status-
788 associated proteins in PBMC using volcano plot analysis on D0, D28, and D57 (two-
789 sided unpaired Welch's t-test). The \log_{10} (B-H adjusted p-value) is plotted as a
790 function of the \log_2 (fold change) between seropositive and seronegative samples (B-

791 H adjusted p-value < 0.05 , $|\log_2(\text{fold change})| > 0.25$). **(B)** Heatmap of the proteins
792 that were significantly regulated in **(A)**. The expression of each protein is shown for
793 both immune response groups and at D0, D28, and D57. **(C)** Heatmap of the most
794 significantly differentially enriched pathways between the seropositive and the
795 seronegative groups generated using GSEA (B-H adjusted p-value < 0.05 , $|\log_2(\text{fold}$
796 $\text{change})| > 0.25$). **(D)** Barplot visualizing the inferred proportions of 20 immune cell
797 types. The average proportions of the 20 immune cell types were derived from the
798 seronegative (Group 0) and the seropositive (Group 1+2) groups. **(E)** Barplots
799 visualizing the average proportions (mean \pm standard error of mean) of B cells, T
800 cells, and several innate immune cells, in the seronegative (Group 0) and
801 seropositive (Group 1+2) groups at three time points. Asterisks in **(D)** and **(E)** indicate
802 the statistical significance based on the Mann-Whitney rank test. P-value: *, < 0.05 ;
803 **, < 0.01 ; ***, < 0.001 .

804 **Figure 4. Comparison of the immune responses in the seropositive and the**
805 **seronegative groups using the serum proteome. (A)** Identification of NAb status-
806 associated proteins in serum using volcano plot analysis on D0, D28, and D57 by the
807 two-sided unpaired Welch's t-test. The B-H adjusted p-values are plotted as functions
808 of the $\log_2(\text{fold change})$ of the mean values between the seropositive and the
809 seronegative samples (B-H adjusted p-value < 0.05 , $|\log_2(\text{fold change})| > 0.25$). **(B)**
810 Heatmap of the proteins that were significantly regulated in **(A)**. The expression of
811 each protein is shown for both immune response groups and at D0, D28, and D57.
812 **(C)** The most significantly enriched networks generated using significantly
813 dysregulated proteins from the serum proteome. Proteins involved in plasma
814 lipoprotein remodeling and neutrophil degranulation are shown with their expression
815 levels in the seropositive and the seronegative groups at three time points. The cutoff
816 of the dysregulated proteins was set at p-value < 0.05 and $|\log_2(\text{fold change})| > 0.25$.
817 The proteins highlighted with a red * had B-H adjusted p-values < 0.05 , while those
818 with a black * were selected from our optimized machine learning models. Group 0:
819 the seronegative group; Group 1+2: the seropositive group.

820 **Figure 5. Proteomics of seropositive and seronegative individuals 180 days**
821 **after CoronaVac[®] vaccination. (A)** Workflow for generating a model to predict the
822 antibody persistence till D180. We discarded participants from Group 0 (the
823 seronegative ones) and those without clinical indicators on D180, the remaining two
824 cohorts: a training cohort (Cohort 3, N = 107) and a test cohort for the validation
825 (Cohort 4, N = 20). **(B)** SHAP values of the machine learning classifier trained with
826 selected PBMC proteins. **(C)** Expression of the selected proteins from the PBMC
827 samples. The asterisks indicate the statistical significance based on the unpaired
828 two-sided Welch's t-test. P-value: *, < 0.05 ; **, < 0.01 ; ***, < 0.001 . Group 3 (N =
829 107): the seronegative group on D180; Group 4 (N = 20): the persistently
830 seropositive group. **(D)** Relative expression of the proteins selected for our model in
831 the different cell type clusters of PBMCs (data from the Human Proteins Atlas(HPA;
832 Karlsson et al., 2021)).

833 **Figure 6. Functional and network analyses of the seropositive and**
834 **seronegative groups' immune responses: a comparison between PBMC and**
835 **serum data. (A)** Chord diagrams of the most enriched pathways based on the
836 significantly dysregulated proteins and the potential biomarker proteins. **(B)** Network
837 analysis of the most significantly enriched pathways (with their p-values) based on
838 the DEPs and the potential biomarker proteins. **(C)** Key PBMC and serum proteins
839 characterized in seronegative and seropositive recipients. Proteins involved in the
840 humoral immune response, neutrophil degranulation, network maps of SARS-CoV-2
841 signaling pathways, and regulation of lymphocyte migration are shown in this network
842 with their corresponding expression levels in the seronegative and the seropositive
843 groups. Group 0: the seronegative group; Group 1+2: the seropositive group; Group
844 3: the group that became seronegative before D180; Group 4: the group that was
845 seropositive at least until D180.

846

847 **Figure S1. Factors associated with seropositivity of neutralizing antibodies at**
848 **D57 and D180, respectively. (A)** Multivariable logistic regression analysis was used
849 to investigate factors associated with the generation of NABs at D57 after adjusting
850 sex, BMI and diastolic blood pressure. **(B)** Multivariable logistic regression analysis
851 was used to investigate factors associated with the persistence of NABs at D180 after
852 adjusting leukocytes, monocytes, RBC, lymphocytes, hemoglobin, LDL, HDL, TG,
853 ALT, and AST.

854 **Figure S2. Quality controls of the proteomics data. (A)** Study design of our TMT-
855 labeling-based quantitative proteomics analysis of PBMCs and sera samples.
856 Together, PBMCs and serum generated 528 peptide samples, including 33 pooled
857 controls, distributed into 33 batches and analyzed using TMTpro 16-plex labeling
858 based proteomics. **(B)** The proteomics data's coefficients of variation were calculated
859 using the abundance of the quantified proteins in the 33 pooled controls of the 33
860 batches. Also, they were computed after removing the outliers. **(C)** Quality control of
861 the technical replicates based on the Pearson correlation coefficients. **(D-E)** PCA
862 analyses were performed on all the proteomics data derived from the PBMC **(D)** and
863 serum samples **(E)**, for three immune response groups on D57 (Group 0, Group 1,
864 and Group 2) and two immune response groups on D180 (Group 3 and Group 4).
865 Group 1: the late seropositive group; Group 2: the early seropositive group.

866 **Figure S3. Machine learning-based prediction of Group 1 (being negative at**
867 **D28 and then converting) and Group 0 (being negative at D28 and never**
868 **converting) before vaccination. (A)** Our machine learning-based predictor was
869 based on PBMC, serum, and both types of proteins. We used the samples from a
870 discovery cohort (Cohort 1, N = 137) to optimize the model's parameters. The model
871 was then tested using a test cohort (Cohort 2, N = 26): the first based on PBMC
872 biomarkers and the second on serum biomarkers. We next developed a third model
873 that was an ensemble of the two previous ones. This third model led to an AUC of
874 0.853, which was higher than using PBMC or serum proteins individually. **(B)** The
875 SHAP values of the five PBMC proteins were prioritized using the machine learning

876 model. **(C)** The SHAP values of the five serum proteins were prioritized using the
877 machine learning model. Identification of NAb status-associated proteins in PBMC
878 **(D)** and serum **(E)** using volcano plot analysis on D0, D28, and D57 (two-sided
879 unpaired Welch's t-test). The \log_{10} (B-H adjusted p-value) is plotted as a function of
880 the \log_2 (fold change) between Group 1 and Group 0 samples (B-H adjusted p-value
881 < 0.05 , $|\log_2(\text{fold change})| > 0.25$).

882 **Figure S4. Immune response and pathway analyses using the PBMC data. (A)**
883 Heatmap of 985 proteins selected using the ANOVA test. Each protein is compared
884 among the three immune response groups (Group 0, 1, and 2) on D0, D28, and D57
885 (p -value < 0.05). Group 0: the seronegative group; Group 1: the late seropositive
886 group; Group 2: the early seropositive group. **(B-D)** Pathways' enrichment based on
887 the proteins selected using the ANOVA test to compare the three immune response
888 groups on D0 (B), D28 (C), and D57 (D) using Metascape (\log_{10} p-value). **(E)**
889 Barplots visualizing the estimated proportions of 20 immune cell types in each PBMC
890 sample. Each column represents a sample; the colors indicate the inferred immune
891 cell components. **(F)** Average proportions of 20 immune cell types, in Group 0, Group
892 1, and Group 2, at three time points. The asterisks indicate the statistical significance
893 based on the Kruskal-Wallis test. P-value: *, < 0.05 ; **, < 0.01 ; ***, < 0.001 . **(G)**
894 Barplots visualizing the estimated proportions of 20 immune cell types, in Group 0,
895 Group 1, and Group 2, at three time points. Different colors indicate the predicted
896 composition of immune cell types.

897 **Figure S5. Immune response and pathway analysis using the serum data. (A)**
898 Heatmap of 129 proteins selected using the ANOVA test. Each protein is compared
899 between the three immune response groups (Group 0, 1, and 2) on D0, D28, and
900 D57 (P -value < 0.05). Group 0: the seronegative group; Group 1: the late
901 seropositive group; Group 2: the early seropositive group. **(B)** Pathways' enrichment
902 based on the proteins selected in **(A)** using Metascape. **(C-D)** Comparison among
903 three immune response groups (Group 0, 1, and 2) of the canonical pathways of
904 proteins in **(A)** by IPA (Kramer et al., 2014).


905 **Figure S6. Immune response and pathway analysis using the PBMC and the**
906 **serum data. (A-B)** Pathways' enrichment analysis of selected PBMC proteins.
907 Specifically, 6331 PBMC proteins and 961 serum proteins were grouped into 12
908 discrete clusters using mFuzz, respectively. This analysis included all the proteins
909 from the PBMC dataset that steadily increased **(A)** or decreased **(B)** over time. And
910 the serum dataset that steadily increased **(C)** or decreased **(D)** over time. The 20
911 most significantly enriched pathways involving these DEPs were analyzed using
912 Metascape.

913 **Figure S7. Immune response and network analysis of the seropositive groups:**
914 **comparison between PBMC and serum data.** The most significantly dysregulated
915 proteins identified using mFuzz from the following groups are here compared: **(A)**
916 upregulated in both PBMC and serum, **(B)** downregulated in both PBMC and serum,

917 **(C)** upregulated in PBMC and downregulated in serum, and **(D)** downregulated in
918 PBMC and upregulated in serum. The Venn diagrams show the overlaps between
919 the PBMC (blue) and the serum proteins (red). Pathways and heatmaps were
920 generated from the overlapping proteins from each pair. **(E)** The most significantly
921 enriched networks generated using the DEPs from **(A-D)**. The proteins involved in
922 the complement system, including platelet degranulation, neutrophil degranulation,
923 and protein-lipid complex remodeling.


Figure 1

A



*Group 0, the seronegative group, participants who were seronegative of neutralizing antibodies (NAb) on D28 and D57.
 Group 1, the late seropositive group, represents participants who were seronegative for NAb on Day 28 but were seropositive on D57.
 Group 2, the early seropositive group, represents participants who were seropositive for NAb on D28 and D57.
 Group 1+2, the seropositive group, Group 1 and Group 2.
 Group 3, the seronegative group on D180. Group 4, the persistently seropositive group, seropositive on D180.

B



C






Figure 2


A




B



C



D



E




Figure 3




Figure 4




Figure 5




Figure 6





Figure S1

A

Seropositive of NAb titers at D57


Univariable analysis

	pvalue	Odd ratio (95%CI)
Age	0.005	0.930(0.884-0.979)
Sex (vs male)	0.042	0.364(0.137-0.963)
BMI	0.027	0.878(0.782-0.985)
Diastolic Blood Pressure	0.030	0.951(0.909-0.995)
Systolic Blood Pressure	0.093	0.970(0.937-1.005)
NAb titers at day 28	<0.001	3.173(1.755-5.737)
Leukocytes	0.757	0.950(0.686-1.315)
Monocytes	0.370	5.804(0.124-271.388)
RBC	0.428	0.698(0.287-1.698)
Lymphocytes	0.854	0.927(0.413-2.081)
Platelets	0.377	1.004(0.996-1.012)
Neutrophils	0.652	0.908(0.596-1.383)
Hemoglobin	0.693	0.995(0.969-1.021)
UA	0.444	0.998(0.993-1.003)
GGT	0.340	1.017(0.983-1.052)
TBIL	0.986	1.001(0.930-1.077)
LDL	0.248	1.457(0.769-2.760)
HDL	0.267	2.542(0.489-13.217)
TC	0.180	1.453(0.841-2.509)
TG	0.914	0.956(0.424-2.157)
Glucose	0.847	1.047(0.655-1.674)
IR	0.262	0.896(0.741-1.085)
Alb	0.119	1.179(0.958-1.449)
CRP	0.922	1.007(0.868-1.169)
Cr	0.865	0.999(0.983-1.014)
ALT	0.538	1.011(0.977-1.046)
AST	0.713	1.011(0.952-1.074)
Drug(vs without drug)	0.688	0.729(0.156-3.400)
MAFLD(vs non-MAFLD)	0.099	2.261(0.857-5.968)
Hypertension(vs non-hypertension)	0.553	1.500(0.393-5.718)
T2DM (vs non-T2DM)	0.562	1.944(0.206-18.367)



Multivariable analysis

	pvalue	Odd ratio (95%CI)
Age	0.136	0.956(0.902-1.014)
Sex (vs male)	0.992	0.994(0.294-3.357)
BMI	0.053	0.855(0.729-1.002)
Diastolic Blood Pressure	0.467	0.977(0.918-1.040)
NAb titers at day 28	<0.001	3.079(1.663-5.698)




B

Seropositive of NAb titers at D180


Univariable analysis


	pvalue	Odd ratio (95%CI)
Age	0.340	0.984(0.950-1.018)
Sex (vs male)	0.061	2.017(0.967-4.208)
BMI	0.699	0.981(0.890-1.081)
Diastolic Blood Pressure	0.634	1.008(0.975-1.043)
Systolic Blood Pressure	0.209	1.018(0.990-1.046)
NAb titers at day 28	0.003	1.121(1.041-1.207)
NAb titers at day 57	0.002	1.030(1.011-1.049)
Leukocytes	0.028	1.334(1.032-1.725)
Monocytes	0.043	16.744(1.100-254.957)
RBC	0.001	3.425(1.618-7.250)
Lymphocytes	0.003	2.748(1.394-5.416)
Platelets	0.060	1.006(1.000-1.013)
Neutrophils	0.390	1.150(0.836-1.580)
Hemoglobin	0.029	1.025(1.002-1.048)
UA	0.087	1.003(1.000-1.007)
GGT	0.089	1.014(0.998-1.031)
TBIL	0.062	0.943(0.888-1.003)
LDL	0.047	1.593(1.007-2.522)
HDL	0.041	0.267(0.075-0.950)
TC	0.036	1.525(1.028-2.261)
TG	0.001	3.010(1.603-5.650)
Glucose	0.449	0.864(0.592-1.261)
IR	0.240	1.115(0.930-1.336)
Alb	0.061	1.156(0.993-1.346)
CRP	0.846	0.983(0.828-1.168)
Cr	0.610	1.003(0.991-1.015)
ALT	0.025	1.024(1.003-1.045)
AST	0.021	1.051(1.007-1.097)
Drug(vs without drug)	0.069	0.422(0.166-1.070)
MAFLD(vs non-MAFLD)	0.084	0.521(0.249-1.092)
Hypertension(vs non-hypertension)	0.181	0.508(0.188-1.370)
T2DM (vs non-T2DM)	0.656	1.657(0.180-15.273)



Multivariable analysis

	pvalue	Odd ratio (95%CI)
NAb titers at day 28	0.043	1.096(1.003-1.198)
NAb titers at day 57	0.043	1.021(1.001-1.041)
Leukocytes	0.422	0.836(0.540-1.295)
Monocytes	0.241	3.551(0.426-29.587)
RBC	0.123	3.260(0.727-14.613)
Lymphocytes	0.085	2.427(0.885-6.657)
Hemoglobin	0.642	0.990(0.949-1.032)
LDL	0.364	0.000(0.000-1.276E+37)
HDL	0.364	0.000(0.000-1.571E+37)
TC	0.362	1.566E+32(0.000-2.488E+101)
TG	0.372	0.000(0.000-1.370E+17)
ALT	0.706	0.990(0.938-1.044)
AST	0.659	1.024(0.921-1.140)










Figure S4


A




B




C




D




E



F




G




All rights reserved. No reuse allowed without permission.

A




B



C

compare_3anova_serum



D




Figure S6

